Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
SGMO Stock Chart & Stats
$0.43
-$0.13(-9.49%)
At close: 4:00 PM EST
$0.43
-$0.13(-9.49%)
Day’s Range― - ―
52-Week Range$0.35 - $1.06
Previous CloseN/A
Volume2.84M
Average Volume (3M)7.65M
Market Cap
$160.68M
Enterprise Value$155.58M
Total Cash (Recent Filing)$30.53M
Total Debt (Recent Filing)$25.42M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding371,684,780
10 Day Avg. Volume4,237,466
30 Day Avg. Volume7,646,780
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)9.04
Price to Sales (P/S)3.56
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue4.73
Enterprise Value/Gross Profit4.73
Enterprise Value/Ebitda-1.51
Forecast
1Y Price Target
$6.00Price Target Upside1295.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$55.38M
Bulls Say, Bears Say
Bulls Say
Durable PharmacologySingle-infusion gene therapy showing durable supraphysiologic enzyme expression and sustained substrate control across organs supports a strong biological rationale for lasting clinical benefit.
Regulatory PathwayFDA acceptance of a rolling biologics license application and agreement to use kidney-function slope as an approval endpoint, together with orphan and expedited designations, strengthens the path toward potential regulatory approval.
Safety ProfileLong-term follow-up reported no late-emerging safety signals and maintained clinical and biochemical benefits, reducing safety-related concerns for approval and physician adoption.
Bears Say
Funding And Execution RiskRequirement to raise significant cash could signal a funding shortfall that risks program timelines or forces less favorable partnership or licensing terms.
Market Reaction RiskThe announced financing plan may prompt negative market reaction and place downward pressure on the stock as investors reassess near-term capital needs and valuation.
Shareholder DilutionA planned gross capital raise in 2026 could dilute existing shareholders and reduce per-share value if new shares are issued.
Sangamo Biosciences News
SGMO FAQ
What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $0.34 and its highest was $1.06 in the past 12 months.
What is Sangamo Biosciences’s market cap?
Sangamo Biosciences’s market cap is $160.68M.
When is Sangamo Biosciences’s upcoming earnings report date?
Sangamo Biosciences’s upcoming earnings report date is May 18, 2026 which is in 77 days.
How were Sangamo Biosciences’s earnings last quarter?
Currently, no data Available
Is Sangamo Biosciences overvalued?
According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
Does Sangamo Biosciences pay dividends?
Sangamo Biosciences does not currently pay dividends.
What is Sangamo Biosciences’s EPS estimate?
Sangamo Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sangamo Biosciences have?
Sangamo Biosciences has 371,684,780 shares outstanding.
What happened to Sangamo Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sangamo Biosciences?
Currently, no hedge funds are holding shares in SGMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sangamo Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (1295.35% Upside)
$6.00 (1295.35% Upside)
Hedge Fund Trend
Increased
By 58.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.70%
12-Months-Change
Fundamentals
Return on Equity
-480.02%
Trailing 12-Months
Asset Growth
-20.33%
Trailing 12-Months
Company Description
Sangamo Biosciences
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
SGMO Company Deck
SGMO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical advancements in Fabry disease and neurology programs, endorsement from the FDA, and an extended cash runway. However, there are ongoing challenges in securing long-term funding and potential regulatory uncertainties. Overall, the highlights outweigh the lowlights, indicating a positive outlook.View all SGMO earnings summariesSGMO Stock 12 Month Forecast
Average Price Target
$6.00
▲(1295.35% Upside)
Technical Analysis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Elicio Therapeutics
―
Caribou Biosciences
―
Ownership Overview
1.39% Insiders
5.17% Mutual Funds
1.16% Other Institutional Investors
88.74% Public Companies and Individual Investors